20240109-国金证券-长春高新-000661.SZ-促卵泡注射液获批上市_辅助生殖管线持续丰富_4页_1mb

Summary of CHANGCHUN GAOXIN Report

• Event: On January 9, 2024, CHANGCHUN GAOXIN announced that its subsidiary CHANGCHUN JINSA DRUG CO., LTD received approval for the drug registration certificate of Recombinant Human Follicle Stimulating Hormone Injection (Recombinant hFSH), a first国产重组促卵泡素水针剂 in the assisted reproduction field, offering higher efficacy and fewer side effects compared to existing options.

• Company Analysis: CHANGCHUN GAOXIN, a leader in the industry, benefits from this as its portfolio expands in assisted reproductive technologies, particularly with recombinant FSH products. The company has increased R&D investment, focusing on innovative platforms across pediatric and adult health sectors, supporting long-term growth.

• Financial Projections: The report maintains a "Buy" rating, with 2023-2025 net profit forecasts showing steady growth (47.8 billion CNY in 2023, 55.1 billion in 2024, 62.2 billion in 2025), and EPS rising from 11.80 CNY to 15.38 CNY, supported by strong revenue growth from its main business.

• Key Risks: Potential challenges include medicare price controls, increased competition in growth hormones, vaccine sales variations, and unmet R&D timelines. Current financial metrics show robust performance but highlight risks from market factors like policy changes.